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Summary
Infection of subcutaneous tissue with Mycobacte-
rium ulcerans can lead to chronic skin ulceration
known as Buruli ulcer. The pathogenesis of this
neglected tropical disease is dependent on a lipid-
like toxin, mycolactone, which diffuses through
tissue away from the infecting organisms. Since its
identification in 1999, this molecule has been
intensely studied to elucidate its cytotoxic and
immunosuppressive properties. Two recent major
advances identifying the underlying molecular
targets for mycolactone have been described. First,
it can target scaffolding proteins (such as Wiskott
Aldrich Syndrome Protein), which control actin
dynamics in adherent cells and therefore lead to
detachment and cell death by anoikis. Second, it
prevents the co-translational translocation (and
therefore production) of many proteins that pass
through the endoplasmic reticulum for secretion or
placement in cell membranes. These pleiotropic
effects underpin the range of cell-specific function-
al defects in immune and other cells that contact
mycolactone during infection. The dose and dura-
tion of mycolactone exposure for these different
cells explains tissue necrosis and the paucity of
immune cells in the ulcers. This review discusses
recent advances in the field, revisits older findingsReceived 12 October, 2015; revised 10 November, 2015; accepted
13 November, 2015. *For correspondence. E-mail rachel.
simmonds@surrey.ac.uk;Tel. (+44) 1483684714;Fax (+44)1483686401.
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medium, provided the original work is properly cited.in this context and highlights current develop-
ments in structure-function studies as well as
methodology that make mycolactone a promising
diagnostic biomarker.Introduction
Mycobacterium ulcerans (MU) infection can cause Buruli
ulcer (BU), a chronic necrotizing skin infection with high
prevalence in rural West Africa (Junghanss et al., 2014;
O’Brien et al., 2014). It may manifest initially as a pre-
ulcerative nodule, plaque or a rapidly progressing
oedematous lesion. Over a few weeks, these lesions
break down to form characteristic ulcers with undermined
edges, which are associated with extensive necrosis
alongside minimal inflammatory response. In contrast to
other pathogenic mycobacteria, which are facultative
intracellular pathogens of macrophages, MU is seen as
extracellular clusters of bacilli lying within areas of
coagulative necrosis that extend some distance from the
site of bacterial colonisation (Forbes et al., 1954). This
observation led to early proposals that MU secretes an
exotoxin (Connor et al., 1965; Connor et al., 1966). A
major breakthrough occurred in 1999 with the purification
and isolation of a cytotoxic molecule from the acetone
soluble fraction of lipid extracts of MU. This lipid toxin,
designated as mycolactone, was shown to be cytopathic
to cultured L929 murine fibroblasts. Intradermal inocula-
tion of purified toxin into guinea pigs produced a lesion
histologically similar to BU with necrosis of subcutaneous
fat. Furthermore, inoculation of an isogenic toxin-negative
mutant of MU caused a granulomatous lesion typical of
the inflammatory response to other mycobacteria with
phagocytosed MU visible within macrophages and none of
the characteristic fat necrosis (George et al., 1999).
Mycolactone is now known to be responsible for the
immunosuppression and tissue necrosis in BU, as well as
the painlessness of BU ulcers; one reason why patients
often delay treatment (Goto et al., 2006).s Ltd
ibution License, which permits use, distribution and reproduction in any
cellular microbiology
18 F.S. Sarfo et al.Mycolactone is a polyketide composed of an invariant
12-membered lactone ring to which two polyketide-derived
highly unsaturated acyl side chains are attached (Fig. 1).
The upper ‘Northern’ chain is invariant, whereas variations
in the ‘Southern’ chain give rise to different congeners of
mycolactone. The initial molecule reported was identified
on thin layer chromatography (TLC) as a light yellow,
ultraviolet-active lipid band with a retention factor value of
0.23 (George et al., 1999). Analysis of the toxin by mass
spectrometry (MS) under microspray conditions showed a
strong peak at m/z 765 with a formula of C44H7009Na
corresponding to the sodium adduct of mycolactone.
Mycolactone synthesis depends on a 174 kb
megaplasmid named pMUM001, which has three large
genes (mlsA1, mlsA2 and mlsB) encoding the modular
type I polyketide synthases as well as accessory genes
(Stinear et al., 2004). MlsA1 and MlsA2 form a nine-
extension module complex that synthesizes the
mycolactone core, while the MlsB is a single polypeptide,
comprising seven extension modules that are required for
the synthesis of the side chain. Accessory proteins, such
as mup045 and mup038, are thought to be required for
joining of the subunits. However, these genes are necessary
(but not sufficient) for mycolactone synthesis (Porter et al.,Fig. 1. Molecular structure of mycolactone A/B. The chemical structure
of mycolactone A/B has a core cyclic lactone ring (C1–C11) and two
polyketide-derived highly unsaturated acyl side chains. The upper
‘Northern’ chain consists of C12–C20 and the longer ‘Southern’ chain is
numbered C1′–C16′. The numbering reflects the natural synthetic
pathway of mycolactone by the polyketide synthase enzymes in MU.
Under common laboratory conditions and light, mycolactone exists as
spontaneously forming geometric isomers centered around the double
bond at C4′C5′ (indicated by thewavy line betweenC5′ andC6′) in a 3:2
ratio. The structure of the variant mycolactone-like molecule 5b is also
shown; this lacks the C8 methyl and the Northern chain.
© 2015 The Authors. Cellular Microbiology P2009; Porter et al., 2013). Variants or congeners of
mycolactone differ in the positions of hydroxyl groups in
the Southern chain and exhibit differences in biological
activity depending on the origin of strains of MU. Pathogenic
human strains from Africa, Australia and China predomi-
nantly produce mycolactone A/B (m/z 765), C (m/z 749) and
D (m/z 779), respectively, but each strain also produces
minor quantities of the other two congeners (Mve-Obiang
et al., 2003). The most cytotoxic congener in vitro is
mycolactone A/B. Notably, other genetically related organ-
isms pathogenic to fish and frogs can also produce variants
of mycolactone E (m/z 737) and F (m/z 723) (Mve-Obiang
et al., 2005; Ranger et al., 2006; Pidot et al., 2008).Kinetics of mycolactone production during Buruli ulcer
pathogenesis and antibiotic treatment
Recent advances in methodology have allowed us, for the
first time, to appreciate how mycolactone concentration
changes in MU infections in experimental animal models
and in human patients. Detection of mycolactone currently
uses approaches that involve the extraction of acetone
soluble lipids from tissue samples. Early experiments
used labelled mycolactone, extracted from MU grown in
C14 (Hong et al., 2008), but more recently, mycolactone
concentration has been quantified by different methods.
Mass spectroscopic (MS) detection of mycolactone
employing high-performance liquid chromatography with
mass spectrometry (LC-MS) to identify the parent ion (m/z)
followed by MS–MS fragmentation to produce character-
istic daughter ions (Hong et al., 2003) is a highly sensitive
and specific approach. The intensities of parent to
daughter ion ratios on mass spectrometry of serial
dilutions of synthetic mycolactone standards are used to
plot calibration curves for mycolactone quantification
(Sarfo et al., 2013; Sarfo et al., 2014). The utility of this
method is limited to highly sophisticated laboratories for
research purposes. Others include assessing cytotoxic
activity against L929 fibroblasts compared with a purified
mycolactone standard. Because L929 fibroblasts are
exquisitely sensitive to mycolactone, this approach can
detect small amounts of mycolactone. The specificity of
this approach is however limited by the fact that other
cytotoxic components generated in infected tissue may
also be present in these preparations (perhaps including
mycolactone’s breakdown products). Another experimen-
tal approach that is undergoing validation involves
fluorescent TLC in which mycolactone A/B, but not most
other acetone soluble lipids, fluoresce under UV light
(Spangenberg et al., 2010). This method involves the
estimation of band intensities relative to mycolactone
standards and may be of utility in endemic countries as it
can be performed without access to expensive and
technically demanding equipment.ublished by John Wiley & Sons Ltd, Cellular Microbiology 18, 17–29
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mycolactone was shown to be present within human BU
lesions (Sarfo et al., 2010). Cytotoxicity assays gave
positive results for 92% of patients tested (mycolactone
concentration estimates ranged from 0.3 to 6μg/punch
biopsy), whereas MS was able to detect mycolactone in
77% of the same patients (mycolactone concentration
estimates ranged from 10ng to 2μg/punch biopsy) (Sarfo
et al., 2014). Furthermore, mycolactone has also been
detected in peripheral blood mononuclear cells (and
nearly all other tissues apart from the brain) of mice after
subcutaneous injection of 300 μg of C14-labelled
mycolactone (Hong et al., 2008) and in the sera of BU
patients by MS (Sarfo et al., 2011), proving that
mycolactone can escape the region of local MU infection.
One of the commonly used models of BU is a mouse
model, in which inoculation of MU into footpads causes
lesions to develop over several weeks. Mycolactone has
now been detected in experimentally infected footpads by
various methods. These studies agree that mycolactone
is detectable by MS (Sarfo et al., 2013) or fluorescent TLC
(Converse et al., 2014) within a few days of the onset of
footpad swelling, which precedes ulceration in this
model. At its peak, it is estimated that an infected footpad
can contain 50–200ng mycolactone (Sarfo et al., 2013;
Converse et al., 2014). Antibiotic treatment is known to
cause a decrease in footpad swelling along with
reduced MU colony counts, and this is associated with
decreased mycolactone concentration. Cytotoxicity
assays revealed mycolactone-like activity to be present
earlier than whole mycolactone molecules (by MS), and
this persisted even after viable bacilli had been eliminated
(Sarfo et al., 2013).
Similarly, standard antibiotic therapy for BU (daily oral
rifampicin and intramuscular streptomycin for 8weeks)
causes a substantial decrease in mycolactone detected in
skin biopsies by both cytotoxicity and MS (Sarfo et al.,
2014). However, in some cases, mycolactone could still
be detected in culture-negative samples suggesting that it
may remain in tissue for a time after the organisms have
been killed. This may explain the clinical observation of
profound variations in the time to healing of similar-sized
BU lesions (Sarfo et al., 2014) because low doses of
mycolactone are known to have wide reaching biological
effects, as discussed in the following section. Alternative-
ly, detection of mycolactone in these lesions may also
imply that viable organisms are still present in some
lesions despite negative cultures; culture is only positive
in 40–60% of untreated BU lesions (O’Brien et al., 2014),
whereas mycolactone is detectable in 77–92%. This
discrepancy has implications for the duration of antibiotic
therapy, currently recommended to be 8 weeks.
Mycolactone is therefore a potential tool for monitoring
the response of individuals with delayed healing.© 2015 The Authors. Cellular Microbiology Published by John Wiley & SonMolecular targets of mycolactone
Recently, two direct molecular targets of mycolactone
have been described. Because both of these targets are
widely expressed, these biological effects of mycolactone
should underpin the previous findings on cellular pheno-
type that will be considered in this review. Furthermore, a
specific target of mycolactone was recently reported to
explain the painlessness of BU lesions (Marion et al.,
2014) Mycolactone was reported to dose-dependently
induce hyperpolarisation of murine neurons and to inhibit
the binding of angiontensin II to the type 2 angiotensin II
receptor (AT2R) with an IC50 of 3μgml
1. While AT2R was
required for this effect, the hyperpolarisation itself was
found to be mediated by AT2R-dependent activation of
phospholipase A2, the release of arachidonic acid by
COX-1 and activation of the K+ channel-TRAAK by
prostaglandin E2 (Marion et al., 2014). It will be important
to investigate this mechanism in BU patients, because the
function (and indeed expression) of AT2R in healthy adult
humans outside of the brain is controversial (Ichiki, 2013).
Wiskott–Aldrich syndrome protein hyperactivation
One of the long-known consequences of mycolactone
exposure on cells cultured in vitro is the cytoskeletal
rearrangement and detachment of cells from the culture
dish. Recently, this was reported to be because of
alterations in actin dynamics and the direct binding of
mycolactone to Wiskott–Aldrich syndrome protein (WASP)
and neural WASP (N-WASP) (Guenin-Mace et al., 2013).
These are members of a family of scaffold proteins
transducing a variety of signals into dynamic remodelling
of the actin cytoskeleton via interaction of their C-terminal
verprolin-cofilin-acidic (VCA) domain with the ARP2/3
actin-nucleating complex [reviewed by Thrasher et al.
(2010)]. Using a combination of biochemical assays,
cellular imaging and animal models, it was reported that
mycolactone can hijack these actin-nucleating factors
(Fig. 2). By disrupting WASP autoinhibition, mycolactone
can lead to uncontrolled activation of ARP2/3-mediated
assembly of actin in the cytoplasm. In HeLa cells, this then
leads to concentration of ARP2/3 in the perinuclear region,
resulting in defective cell adhesion and directional
migration. Reductions in the re-adhesion of dissociated,
mycolactone-treated, HeLa cells could be restored by
co-administration of the N-WASP inhibitor wiskostatin,
supporting this.
Inhibition of co-translational translocation via Sec61
In addition to cytopathic effects, another well-established
activity of mycolactone is the inhibition of cytokine
production. Recently, the molecular mechanism underly-
ing this was also reported, as mycolactone profoundly
inhibits the function of the Sec61 translocon. Thiss Ltd, Cellular Microbiology 18, 17–29
Fig. 2. Mycolactone causes hyper
activation of WASP. WASP and
N-WASP are modular scaffolding
proteins that exist in auto-inhibited
conformation in which the VCA
(verprolin-cofilin-acidic) domain
(yellow) is occluded by an
intramolecular interaction (dotted line;
a). Activation of WASP and N-WASP
occurs by disruption of the
intermolecular interaction by a variety
of ligands including the cell cycle
regulator CDC42 and binding/
activation of the Arp2/3 complex (b).
The VCA domain of WASP, Arp2/3
complex and G-actin forms a
nucleating centre for incorporation of
actin subunits for growth of actin
filaments (c, d, e). Actin polymerisation
and formation of cytoskeleton is crucial
for endocytosis, cell-to-cell adhesion
and migration of cells. Mycolactone
hijacks and disrupts the auto-inhibited
state of WASP/N-WASP (f). This
forces WASP into the activated state
with Arp2/3 bound (g). Mycolactone
causes increases in the rate of Arp2/3-
mediated actin assembly, outside of
normal cellular control (h) Unregulated
actin polymerisation leads to defective
cytoskeleton formation and loss cell
adhesion and apoptosis (i, j).
20 F.S. Sarfo et al.essential ‘gate keeper’ is responsible for protein translo-
cation into the endoplasmic reticulum (ER), something that
must occur for about 30–50% of proteins made by
mammalian cells, not only cytokines but also membrane
receptors and proteins that function inside the ER itself.
Normally, most ER-transiting proteins undergo ‘co-
translational translocation’, i.e. the ribosome becomes
attached to the ER membrane via Sec61 accessory
proteins and the signal peptide, and the translating
peptide is synthesized directly into the ER lumen for
folding by chaperones [reviewed by Zimmermann et al.
(2011)]. Using detailed biochemical assays, on a range of
different proteins, it was shown that the presence of
mycolactone prevents this from taking place, and instead
the proteins are translated in the cytosol where they are
marked for rapid destruction by the proteasome (Hall
et al., 2014) (Fig. 3). Formal evidence clearly supported
translocation blockade affecting IL-6, prepro-α factor and
β lactamase (conventionally secreted proteins; a
cytokine and two non-mammalian model proteins used
routinely in translocation assays), COX-2 (an ER-
resident enzyme), tumour necrosis factor and
thrombomodulin (both type I membrane proteins).
Furthermore, cessation of production of N-linked glyco-
sylated proteins was demonstrated by metabolic label-
ling, indicating that potentially hundreds of proteins are
influenced by this mechanism in every cell. Therefore,© 2015 The Authors. Cellular Microbiology Pwhile the purpose of this study was to explain the lack of
inflammation in BU, the identified mechanism probably
impacts the pathogenesis in multiple ways (Hall et al.,
2014; Ogbechi et al., 2015).Cellular consequences of mycolactone exposure
The biological function of mycolactone A/B has been
intensively studied in vitro and in vivo by using purified
lipid extracts from cultured MU, chemically synthesized
mycolactone, or by comparing the effects of wild-type MU
with those of mycolactone-negative mutant strains with
broadly comparable results. Mycolactone seems to diffuse
passively across the cell membrane because uptake of
fluorescently labelled mycolactone by fibroblasts was both
non-saturable and non-competitive with excess
mycolactone (Snyder et al., 2003). Bodipy-mycolactone
appears to be localized in the cytosol but is excluded from
the nucleus (Chany et al., 2011). At least some of the
effects of mycolactone have also been shown to be
irreversible; for example, suppression of cytokine produc-
tion still occurs 24–48h after mycolactone is removed
from cell culture media (Hall et al., 2014). In the following
review of the cellular actions of mycolactone, we have
focused on the time of exposure and dose of mycolactone
and revisited some of the findings in the light of our new
knowledge about the molecular mechanisms.ublished by John Wiley & Sons Ltd, Cellular Microbiology 18, 17–29
Fig. 3. Mycolactone inhibits the co-translational translocation of proteins via Sec61. Sec61-dependent, ER-transiting proteins are derived from
mRNAs (a) and usually have a signal peptide sequence at the amino terminus (b). Once this is formed, translation pauses and the signal peptide is
recognized by the SRP (not shown), which transports the ribosome/mRNA/nascent peptide complex to the Sec61 complex at the ER membrane (c).
The hydrophobic signal peptide interacts with Sec61 and translation continues, directly into the ER lumen (d); a process further facilitated by
chaperones such as BiP (not shown). A similar process occurs for transmembrane proteins (TNF), monotypic proteins (COX-2) and conventionally
secreted proteins (IL-6). In the presence of mycolactone, translocation cannot occur (e) so translation takes place in the cytoplasm instead (f), and
the proteins, recognized by the cell as being in the wrong compartment, are destroyed almost immediately by the 26S proteasome (g). This means
that induced proteins can never be detected, and constitutive proteins are lost from the cell as they cannot be replaced during normal protein
recycling.
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Much research has been directed towards the effects of
mycolactone on immune cells, in order to better
understand the mechanism of immune suppression, which
affects both innate and adaptive immune responses. For
instance, in mycolactone-negative strains of MU
(Adusumilli et al., 2005), and during antibiotic treatment
of BU patients (Schutte et al., 2007), infection
is associated with granulomas that are initiated by infected
macrophages. However, in active BU, these are
rarely observed, presumably because of the action of
mycolactone.
Monocytes and macrophages. Macrophages (and their
circulating precursors, monocytes) are vital components of
innate and anti-mycobacterial immunity. Despite the fact
that mycolactone has been shown to interfere with
phagocytosis by J774 macrophages (Adusumilli et al.,
2005), a transient intra-macrophage growth phase has© 2015 The Authors. Cellular Microbiology Published by John Wiley & Sonbeen shown for MU (Torrado et al., 2007). Once
internalized, the toxin also modulates macrophage
microbicidal activity triggered by IFN-γ via inhibition of
phagosome maturation/acidification and nitric oxide
production with consequent increased intra-macrophage
bacterial load (Torrado et al., 2010). Mycolactone-
negative strains of MU survive better inside J774
macrophages (Adusumilli et al., 2005), and wild-type
infected macrophages eventual ly succumb to
mycolactone’s cytotoxic effects leading to the predom-
inant finding of MU in tissue as extracellular clusters of
bacilli. Macrophages are sensitive to mycolactone’s
cytotoxic effect in vitro but at relatively high doses and
after prolonged exposure (several days) (Simmonds
et al., 2009; Hall et al., 2014). Notably, during antibiotic
treatment of BU patients, MU can once again be
detected within macrophages (Schutte et al., 2009).
Mycolactone also affects the function of monocytes/
macrophages independently of contact with MU. Purifieds Ltd, Cellular Microbiology 18, 17–29
able 1. Inhibition of cytokine, chemokine and other immune
odulators by mycolactone.
ummary of findings of multiple publications that have reported the
ffect of mycolactone directly on the production of various cytokines,
hemokines and other proteins by monocytes (Simmonds et al., 2009),
acrophages (Hall et al., 2014), dendritic cells (Coutanceau et al.,
007), primary T-cells (Phillips et al., 2009, Guenin-Mace et al. 2011),
-cell lines (Pahlevan et al., 1999, Boulkroun et al., 2010) and
ndothelial cells (Ogbechi et al., 2015). Colour coding is as follows:
ed, profound inhibition; orange, some inhibition; yellow, little inhibition;
reen, no inhibition; dark green, increased expression;white, not studied
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cytokines, chemokines, other secreted immunemodulators
(Table 1) and intracellular effector molecules such as
COX-2 (Simmonds et al., 2009; Hall et al., 2014) at doses of
50–125 ngml1 mycolactone. While IL-1β was also
suppressed by mycolactone, this was less efficient than
for the other, conventionally secreted, cytokines
(Simmonds et al., 2009). In the context of our improved
understanding of mycolactone’s inhibition of Sec61 trans-
location, it is interesting to note that IL-1β does not undergo
this process and is instead released from a cytoplasmic
pro-IL-1β precursor by caspases activated via the
inflammasome (Rathinam et al., 2012).
Notably, in the process of uncovering the protein
translocation defect caused by mycolactone that explains
the loss of these proteins (see discussions earlier), the
transcription or export (Simmonds et al., 2009) and
translation (Hall et al., 2014) of these proteins were not
directly affected. Mycolactone had no effect on the TLR-
dependent activation of the MAPK and NF-κB signalling
pathways, ribosomal association was normal and there
was no evidence of conventional cellular stress during
short exposure times (<5 h). Recently, hyperpolarisation
of RAW264.7 macrophages was found to occur rapidly
(within 20mins) of high dose (5μgml1) mycolactone
exposure, but not at lower doses (Marion et al., 2014).
Dendritic cells. Both immature and mature primary human
dendritic cells are sensitive to mycolactone-induced
apoptosis at concentrations above 50 ngml1. Below
this concentration, mycolactone strongly affected the
maturation of dendritic cells, inhibited the induction of
co-stimulatory molecules, limited their migratory properties
but not their phagocytic activity and exerted an apparently
selective effect on the secretion of inducible chemokines
by dendritic cells in response to Toll-like receptor ligands
(Coutanceau et al., 2007). In particular, mycolactone
blocked the production of chemokines, whereas the
expression of inflammatory cytokines was less affected
at the doses used (Table 1). As key players in the initiation
of adaptive immune responses, mycolactone-dependent
suppression of co-stimulatory molecules, chemokines and
cytokines would severely inhibit the capacity of dendritic
cells to prime cellular immune responses. The loss of co-
stimulatory molecules, cytokines and chemokines likely
results from blockade of Sec61 translocation in these
cells.
T-cells. Experiments using a crude preparation of
mycolactone were the first to suggest that the immuno-
suppressive properties of mycolactone extend to
lymphocytes because it inhibits production of IL-2 by
activated T-cell lines (Pahlevan et al., 1999), a finding later
confirmed (Phillips et al., 2009; Boulkroun et al., 2010).
Mycolactone also profoundly inhibits the phorbol myristateublished by John Wiley & Sons Ltd, Cellular Microbiology 18, 17–29
Mycolactone and pathogenesis of Buruli ulcer 23acetate (PMA)/ionophore-induced production of many
cytokines and chemokines by primary human CD4+ T
lymphocytes. Antigen-dependent production of many
Th-1, Th-2 and Th-17 cytokines by T-cells from BU
patients was also diminished (Phillips et al., 2009)
(Table 1). Defective production of IFN-γ in MU antigen
stimulated peripheral blood cells from patients with
active BU disease has been reported using various
assays (T-cell anergy) (Gooding et al., 2003; Prevot
et al., 2004; Westenbrink et al., 2005; Phillips et al.,
2006), providing further evidence of a lack of co-
stimulation by dendritic cells. This resolves after either
surgical excision of ulcers (Yeboah-Manu et al., 2006)
or after curative antibiotic therapy (Schutte et al., 2007;
Sarfo et al., 2009) supporting the involvement of
mycolactone in these defects. Notably, primary T-cells
are relatively resistant to the cytotoxic effects of
mycolactone at concentrations of up to 1 μgml1
(Boulkroun et al., 2010; Guenin-Mace et al., 2011).
Mycolactone also has profound effects on the crucial
process of T-cell homing in vivo, because subcutaneous
administration of large doses (50 or 100 μg) of
mycolactone leads to massive depletion of T-cells in
peripheral lymph nodes (PLNs) (Guenin-Mace et al.,
2011). This was associated with defective expression of
the cell adhesion/homing receptor L-selectin (CD62-L).
Pre-exposure of T-cells to 100 ngml1 mycolactone for
16 h severely impaired the capacity of T-cells to reach
peripheral lymph nodes after adoptive transfer, respond
to chemotactic stimuli and expand upon antigenic
stimulation in vivo.
With hindsight, it now seems likely that the expres-
sion defects for these ER-transiting proteins may be
mediated by translocation blockade. It also helps
explain some of the contradictory findings of the
previous studies. For instance, when investigating the
mechanisms by which mycolactone modulates IL-2
production after antigenic stimulation in Jurkat T-cells,
identified mechanisms included reductions in reporter
gene activity for NF-κB, AP-1, NFAT/AP-1 and the IL-2
promoter. Conversely, despite ionomycin/PMA
activation-induced IL-2 production being strongly sup-
pressed by mycolactone, this was associated with
increased activation of AP-1 and the IL-2 promoter
(Boulkroun et al., 2010). Furthermore, mycolactone was
found to reduce levels of L-selectin, without affecting its
key transcription factor KLF-2. Here, mycolactone also
reduced the expression of microRNA let-7b, although
over-expressing it could not restore the ability of the
T-cells to produce L-selectin protein. These examples
highlight the important point that translocation blockade
effectively ‘trumps’ any effect of pre-translocation
events. Even if transcription or translation of a particular
gene is increased or decreased by mycolactone; if the© 2015 The Authors. Cellular Microbiology Published by John Wiley & Sonsynthesized protein cannot be translocated into the ER,
it cannot be produced by an affected cell.
Mycolactone exposure also has effects on the cytosolic
component of T-cells that are not confounded by
translocation blockade. Mycolactone rapidly (within
30min) alters the expression of several microRNAs
including let-7b (Guenin-Mace et al., 2011). Let-7b-
mediated fine-tuning of many unidentified target genes
would be expected to lead to changes in cellular
phenotype. For instance, caspase-3 was recently de-
scribed as a target of let-7b in mesenchymal stem cells
(Ham et al., 2015), suggesting that reduced let-7b may
contribute to apoptosis in T-cells. Furthermore,
mycolactone exposure for 24 h led to hyperactivation of
the Src-family kinase, Lck, and was associated with
depletion of intracellular calcium stores and down-
regulation of T-cell receptor (CD3) expression (Boulkroun
et al., 2010).
Neutrophils. Bacterial infection is normally associated with
influx of neutrophils into infected tissue. This is notably
absent in the necrotic centre of BU lesions, but it is seen in
surrounding tissue (Hayman et al., 1985; Hayman, 1993).
Neutrophil chemotaxis towards MU is poor compared with
Mycobacterium marinum, but the defect is probably not
because of mycolactone as the same also applied to a
mycolactone-negative mutant strain (Adusumilli et al.,
2005). Neutrophils are naturally short-lived, but
mycolactone-dependent toxicity was evident within 4 h at
very high doses (5.3μgml1) and was enhanced at lower
doses (1 μgml1) after 24 h.
Skin-resident non-immune cells
A diverse range of different cell types are found within
skin tissue. These include fibroblasts, adipocytes, endo-
thelial cells, keratinocytes, neurons and muscle cells. The
effect of mycolactone on each of these cell types has now
been studied.
Fibroblasts. Dermal fibroblasts are one of the main
constituents of skin dermis, and while no study has
examined the effect of mycolactone on primary human
skin fibroblasts, L929 mouse fibroblasts are the most
mycolactone-sensitive cell identified to date. Serial dilu-
tions of mycolactone down to 0.025 ngml1 led to a
cytopathic effect with cytoskeletal rearrangement at 12 h,
rounding up of cells within 24 h and detachment from the
plate by 48 h (George et al., 1999). We can now consider
that this may be caused by the hyperactivation of WASP.
The changes were associated with cell cycle arrest in the
G0/G1 phase, and after 3–5 days, L929 cells undergo
apoptotic cell death at mycolactone concentrations as low
as 0.002 ngml1 (George et al., 2000). At higher
concentrations (15μgml1), mycolactone causes rapids Ltd, Cellular Microbiology 18, 17–29
24 F.S. Sarfo et al.changes in cell permeability leading to cell death by
primary necrosis (Adusumilli et al., 2005).
Adipocytes. Adipocytes form the fatty layer of the
subcutis within which MU is often found (Junghanss
et al., 2014). Histological examination of MU-infected
guinea pig skin (George et al., 2000) and human skin
(Walsh et al., 2005) shows evidence of adipose cell
death by apoptosis.
To date, the effect of mycolactone has only been
investigated on the human cell line SW872, derived
from a liposarcoma (Dobos et al., 2001). It has recently
been established that these cells express markers
consistent with preadipocytes, but no adipocyte
markers including FABP4 or the presence of lipid
droplets (Nativel et al., 2013). Nevertheless, these
cells seem relatively resistant to prolonged exposure to
1 μgml1 mycolactone, with even 5 days exposure
leading to only low levels of apoptosis and higher
levels of necrosis (Dobos et al., 2001). In these cells,
cellular cytotoxicity ascribed to MU was rather
suggested to be becuase of other components of the
filtrate such as lipoprotein complexes.
Endothelial cells. Endothelial cells pervade the skin tissue,
both in the microvasculature and lining the larger arteries
and veins. They play important roles in the immune
response and also a key role in the maintenance of
intravascular fluidity by regulating blood coagulation. Re-
cently, it was demonstrated that primary human dermal
microvascular endothelial cells are highly sensitive to as little
as 7ngml1mycolactone (Ogbechiet al., 2015). These cells
died by apoptosis after 3–4days exposure, but within 24h, it
caused the depletion of the anticoagulant receptor
thrombomodulin from the surface of the cells. As a result,
mycolactone-exposed cells lose their crucial ability to
activate protein C, a key anticoagulant protein. Other cell
surface molecules (PECAM-1, ve-Cadherin and the endo-
thelial cell protein C receptor) were more resistant to
mycolactone but were still reduced. Loss of thrombomodulin
was shown to be via Sec61 translocation blockade, and
because this is a constitutively expressed protein, it was lost
steadily from the cells at the known turnover rate. Notably,
thrombomodulin was also reduced in the endothelial cells of
BU patient biopsies and was associated with fibrin
deposition in the tissue.
Keratinocytes. Keratinocytes display an unusual pheno-
type in BU. While most cells become necrotic, the
epidermis becomes hyperplastic and psoriatic (Junghanss
et al., 2014). These cells have a central role in wound
healing and repair, forming a protective epithelial barrier
over the wound bed. Thrombomodulin expression by
keratinocytes in the epidermis of some BU patients was© 2015 The Authors. Cellular Microbiology Pfound to be decreased (Ogbechi et al., 2015), although it is
not yet clear what the relevance of this is.
In purified systems, mycolactone causes rounding up
of primary human keratinocytes after 24 h exposure to
>30 ngml1 mycolactone (Gronberg et al., 2010),
although most cells were still alive at this time. Once
again, this may result from WASP-dependent mecha-
nisms. Cell death occurred between 48 and 72 h after
exposure to 100 ngml1 and above, although sub-
cytotoxic doses seemed to actually increase the pro-
liferation of keratinocytes slightly. Cytotoxic doses
(300 μgml1) were associated with rapid generation of
reactive oxygen species (ROS) within 45 mins of
exposure that could be completely prevented by the
ROS inhibiting substance deferoxamine. This Fe2+
chelator could efficiently block mycolactone’s cytotoxic
effects as assessed by neutral red uptake (an indicator
of lysosome numbers) but was less efficient at restoring
metabolic activity as assessed by the vital stain WST-1
(Gronberg et al., 2010).
Neurons. Loss of pain sensation in BU lesions has long
been known and can also be detected during experi-
mental infection with MU in the mouse footpad model
using nociceptive reflex tests utilising von Frey filaments
and foot retraction (Goto et al., 2006) or thermal stimuli
and tail-flick test (Marion et al., 2014). Both found a
reduced perception of pain in swollen/oedematous
infected footpads around 5–7weeks after infection (Goto
et al., 2006; Marion et al., 2014), but in longer infections
that resulted in greater erosion of the footpad and
ulceration pain reception appeared to return (Goto
et al., 2006). Hypoesthesia has been reported to be
dependent on the expression of AT2R, because genetic
knockout of this gene resulted in restoration of normal
latency period for sensing of pain from 11 to 8 s (Marion
et al., 2014).
There is disagreement over whether nerves are
degenerated in these models. Early work showed that
MU invaded the nerves in the perineurium and extended
to the endoneurium with vacuolar degeneration of myelin-
forming Schwann cells and some swollen nerve bundles
massively invaded by acid-fast bacilli (Goto et al., 2006).
Furthermore, injection of 100μg purified mycolactone also
induced nerve damage; nerve bundles showed intraneural
haemorrhage, neutrophilic infiltration and loss of Schwann
cell nuclei with ultrastructural evidence of vacuolar change
of myelin (En et al., 2008). These studies implicated
mycolactone in the direct destruction of nerves; however, in
a more recent study, mycolactone induced analgesia
without ultrastructural evidence of neural degeneration
(Marion et al., 2014). Indeed, in tissue culture, primary
murine hippocampal neurons seem remarkably resistant to
mycolactone’s cytopathic effect, only displaying significantlyublished by John Wiley & Sons Ltd, Cellular Microbiology 18, 17–29
Table 2. Structure-function studies of mycolactone variants.
a. The lowest concentration of mycolactone inducing cell rounding at 24 h or 48 h.
b. The LC50 for induction of apoptosis by flow cytometry using annexin V/PI staining at 48 h (Scherr et al., 2013).
c. The IC50 for loss of metabolic activity by quantification of Alamar Blue staining at 48 h (Scherr et al., 2013).
d. The approximate proportion of cells rounded up at 48 h after treatment with the compound at a concentration of 10 μM (Chany et al., 2011).
e. The approximate proportion of cells that are permeable to trypan blue at 48 h after treatment with the compound at a concentration of 16 μM
(Guenin-Mace et al., 2015).
f. Approximate affinity of binding to WASP in vitro by competitive ELISA (Chany et al., 2014).
g. Approximate ability to prevent the production of IL-2 by PMA/ionomycin activated Jurkat T cells (Guenin-Mace et al., 2015).
h. Mve-Obiang et al. (2003).
i. Scherr et al. (2013).
j. Chany et al. (2011).
k. Has a cyclohexyl ester in place of the core.
l. Did induce 100% rounding at 50 μM.
m. Different baseline molecules: Simplified core (desmethyl C8) so activity of variants compared with {20a} or [4b].
n. Different baseline molecules: Simplified core (desmethyl C8) and lacking the Northern chain so activity of variants compared with [5b].
Compound numbers are given in bold: <>, (Scherr et al., 2013); {}, (Chany et al., 2011); [], (Chany et al., 2014, Guenin-Mace et al., 2015).
Mycolactone A/B has a m.w. of 743; therefore, 1 μM=743 ngml1, 10 μM ≈ 7.4 μgml1 and 16 μM ≈ 12 μgml1. Other congeners of mycolactone have,
where necessary, been converted from ngml1 values reported in the original reference according to their molecular weight. Colour coding is as follows:
Red, profound inhibition; orange, some inhibition; yellow, little inhibition; green, no inhibition; dark green, increased expression; white; activity of
mycolactone A/B.
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26 F.S. Sarfo et al.increased 24 h cell mortality in 20μgml1 mycolactone
(Marion et al., 2014).Structure-function studies of mycolactone
Because base hydrolysis of mycolactone (separating the
lactone core and Northern chain) was shown to result in
a molecule with ~1000-fold reduced cytopathic activity
towards L929 fibroblasts (Mve-Obiang et al., 2003), it
has been clear that the virulence of the molecule
requires the Southern polyketide side chain. Recent
advances in chemical synthetic approaches have facil-
itated the production of many variants of mycolactone
providing more detailed insight into the relationship
between structure and function (Table 2). These have
examined not only the cytopathic effect against L929
fibroblasts (although this is the most widely used assay)
but also direct binding to WASP and immunosuppres-
sive activity (suppression of IL-2 production by Jurkat
T-cells). Discussion of these findings uses the common
numbering system for the carbons in the ‘wild-type’
mycolactone A/B molecule (Fig. 1). Furthermore, because
these studies by definition compare compounds with
differentmolecularweights, theyaremore commonly reported
using molar concentrations. For reference, a 200ngml1
preparation of mycolactone A/B (sufficient to elicit a
functional effect on most cells) is equivalent to 0.27μM.
One complication in understanding these data result
from the fact that, in order to greatly simplify their
synthesis, there is a whole class of mycolactone-like
molecules that lack the methyl group at C8 in the lactone
core (so-called C8-desmethyl mycolactone) (Chany et al.,
2011; Chany et al., 2014; Guenin-Mace et al., 2015).
Compared with the ‘wild-type’ molecule, this has reduced
activity (the lowest dose with cytopathic activity is 5μM
and the IC50 for IL-2 is >4μM vs. 40 nM for the ‘wild-type’
molecule in both cases) and binds less well to WASP (IC50
97μM vs. 32μM). However, tantalisingly, this activity can
be restored by removing the Northern chain (IC50 for IL-2;
1.2μM, IC50 for WASP; 22μM). In some of the investiga-
tions of structure/function, this molecule (named 5b; Fig. 1)
is the base-line molecule that has been altered to
investigate the effect of changes to the Southern chain
(Guenin-Mace et al., 2015).
Taken together, these studies clearly demonstrate that
the lactone core alone has no discernible biological
activity (Chany et al., 2011; Chany et al., 2014).
Furthermore, variations in the Northern chain are gener-
ally well-tolerated, such as the addition of different
functional groups (including fluorescent tags and biotin)
at C14 or C20 (Chany et al., 2011; Scherr et al., 2013;
Chany et al., 2014; Guenin-Mace et al., 2015). On the
other hand, the Southern chain is much more sensitive to
even small perturbations in structure. Similar to chemical© 2015 The Authors. Cellular Microbiology Pmodification of natural mycolactone A/B, truncation of the
Southern chain to C6′ or C2′ (Scherr et al., 2013), or
completely removing it (Chany et al., 2011) results in a
molecule with much reduced cytopathic activity. The
pattern and stereochemistry of the hydroxyl groups on
the Southern chain is also important. While this had
already been inferred by differences in the biological
activity of naturally occurring conjoiners, these detailed
studies have taken this much further. Nearly any change
to the Southern chain reduces the molecule’s immuno-
suppressive activity. Molecules completely lacking hy-
droxylation at C12′, C13′ and C15′ have lost most
cytopathic and immunosuppressive activity (Chany et al.,
2011; Scherr et al., 2013). Altering the stereochemistry of
C12′ and C13′ also tend to have the effect of reducing
the molecule’s activity, depending on the precise context
of the change, but alteration at C15′ seems to have little
effect (Guenin-Mace et al., 2015). The functional impor-
tance of the Southern chain is highlighted by the
biological activity of this polyketide without the core or
Northern chain. This molecule has near-normal affinity for
WASP (Chany et al., 2014) and retains some cytopathic
activity when used at 16μM (Guenin-Mace et al., 2015).
The mycolactone-like molecule 5b (C8 desmethyl and
lacking the Northern chain) is of particular interest
because it retains the ability to suppress inflammation
while having significantly reduced cytopathic activity. The
lowest dose inducing a cytopathic effect in L929 fibro-
blasts has not been reported, but at doses of 10μM and
16μM, it has ~50% cytopathicity (Chany et al., 2011;
Guenin-Mace et al., 2015) and considerably higher
concentrations (16μM vs. 26 nM) were required to have
a similar impact on the attachment/spreading of cells on a
tissue culture surface (Chany et al., 2014). Further
modification of this molecule by altering the stereochem-
istry, or constraining the molecule by the addition of
aromatic rings within the polyketide chain, could not
further enhance this desirable phenotype (Guenin-Mace
et al., 2015). However, 5b is well-tolerated following
intraperitoneal injection into mice where it shows highly
promising anti-inflammatory effects in models of chronic
skin inflammation and rheumatoid arthritis. It may there-
fore have therapeutic potential in the future as a potential
immunosuppressant in diseases outside the realm of BU.Conclusion
The mycolactones are a unique and fascinating class of
molecules. Not only are they central to the understanding
of BU pathogenesis, they are also potentially important in
the diagnosis and monitoring of BU. In the wider context,
they are also helping us understand fundamental aspects
of cell biology; mycolactone is one of only a handful of
molecules that are capable of blocking translocation.ublished by John Wiley & Sons Ltd, Cellular Microbiology 18, 17–29
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molecular investigations; not least obtaining the chemi-
cally pure material because mycolactone production in
the laboratory is arduous and has several unstable
intermediates. Synthetic mycolactone is preferable over
compounds purified from MU becaue difficulties remain in
the purification process, and MU itself is a slow-growing
organism requiring high-level containment for culture.
Furthermore, the physical characteristics of this lipid-like
molecule lend it an inherent ‘stickiness’, which can
complicate analysis. This, together with its low antigenicity
and immunosuppressive activity have hampered genera-
tion of mycolactone-specific antibodies that could
demonstrate the location and concentration of
mycolactone within BU lesions and be used in biochem-
ical assays. Novel approaches under development include
synthesis of recombinant antibodies against mycolactone
and mycolactone specific complexes using phage and
yeast display methods (Naranjo et al., unpublished
observations). Such resources are expected to be of
great utility in the future.
Despite these challenges, the past 10 years have
yielded significant advances in our understanding of the
biological activity of mycolactone. Central to this progress
is the proposition of molecular mechanisms underpinning
its cytotoxic and immunosuppressive properties. We
eagerly await ratification of these findings by way of
independent confirmation from different laboratories to
demonstrate the commonality of the effects. Nevertheless,
it is now clear that the interplay between mycolactone’s
cytotoxic and immunosuppressive effects varies depend-
ing on the cell the toxin is interacting with, the duration of
exposure and the dose. These pleiotropic effects work
together to create a complicated picture in the evolving
lesion, whereby different functional effects may be
apparent at the core of infection where the mycolactone
concentration is highest, compared with the outer edge of
biologically relevant mycolactone concentrations furthest
from the clusters of MU. Intriguingly, this suggests that
mycolactone may be operating via each or all of the
described mechanisms in different cells at different times.
This is especially true if you consider translocation
blockade because of the large range of potentially affected
proteins. Around 30–50% of protein coding genes have a
signal peptide, but the response would be predicted to be
dependent on the specific combination of such proteins
expressed by a specific cell/condition and their sensitivity
to mycolactone-dependent blockade.
In the face of this complexity, the simple facts remain
that mycolactone is the cause of the tissue necrosis, the
impaired clearance of MU infection and the painlessness
of the ulcers. The recent development of techniques for
detection and quantification of mycolactone within host
tissues has further deepened our understanding of the© 2015 The Authors. Cellular Microbiology Published by John Wiley & Sonrelationship between this toxic macrolide and clinical
disease and has opened up a new vista for utilising
mycolactone as a diagnostic and prognostic biomarker for
the management of this neglected tropical disease.
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